Testing a new drug for active lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with SLE (lupus) for at least 12 weeks and your lupus is currently active (with a SLEDAI score of 8 or more, or 6 or more if you also have low complement or positive anti-dsDNA antibodies).
- You have had a positive ANA test (1:80) or positive anti-dsDNA/anti-Sm antibodies in the last year or at screening.
- You are taking at least one standard lupus medicine (like prednisone, hydroxychloroquine, or an immunosuppressant) at a stable dose for at least 4 weeks.
- You are not pregnant, breastfeeding, and agree to use reliable birth control if needed during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This trial tests an investigational injection called CM313 for people with active lupus (systemic lupus erythematosus). It aims to see if the drug can help reduce lupus symptoms and control the disease.
This trial tests a new drug called 626 for people with systemic lupus erythematosus (SLE). It aims to see if the drug is safe and effective at reducing disease activity.
This trial tests an investigational drug called MIL62 for people with systemic lupus erythematosus (SLE) that is still active despite standard treatments. The goal is to see if MIL62 can better control disease activity.
This study tests a new investigational drug called SCTC21C for people with moderate-to-severe systemic lupus erythematosus (SLE). The goal is to see if the drug can help control lupus symptoms and reduce disease activity.
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
Hear when a new System Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.